Resonance Health (ASX:RHT) Ending Cash Position: A$2.69 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Resonance Health Ending Cash Position?

Resonance Health ASX:RHT +7.69% Ending Cash Position is A$2.69 Mil as of Dec. 2025. The stock has 8 warning signs investors should review.

Resonance Health's Ending Cash Position for the quarter that ended in Dec. 2025 was A$2.69 Mil.

Resonance Health's quarterly Ending Cash Position declined from Dec. 2024 (A$3.51 Mil) to Jun. 2025 (A$2.98 Mil) and declined from Jun. 2025 (A$2.98 Mil) to Dec. 2025 (A$2.69 Mil).

Resonance Health's annual Ending Cash Position increased from Jun. 2023 (A$6.36 Mil) to Jun. 2024 (A$6.86 Mil) but then declined from Jun. 2024 (A$6.86 Mil) to Jun. 2025 (A$2.98 Mil).

Resonance Health Ending Cash Position Related Terms

Resonance Health Ending Cash Position Historical Data

* Premium members only.

The historical data trend for Resonance Health's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Resonance Health Ending Cash Position Chart

Resonance Health Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Ending Cash Position
Get a 7-Day Free Trial Premium Member Only Premium Member Only 8.86 6.78 6.36 6.86 2.98

Resonance Health Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Ending Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5.90 6.86 3.51 2.98 2.69

Resonance Health Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

Resonance Health's Ending Cash Position for the fiscal year that ended in Jun. 2025 is calculated as

Ending Cash Position= Beginning Cash Position+Net Change in Cash
=6.854+-3.877
=2.98

Resonance Health's Ending Cash Position for the quarter that ended in Dec. 2025 is calculated as

Ending Cash Position=Beginning Cash Position+Net Change in Cash
=2.977+-0.286
=2.69

Frequently Asked Questions Learn more about Ending Cash Position →
What does a Ending Cash Position of A$2.69 Mil mean?
Resonance Health (ASX:RHT) has a Ending Cash Position of A$2.69 Mil as of Dec. 2025. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Resonance Health and its competitors.
Is Resonance Health's Ending Cash Position too high?
Resonance Health's current Ending Cash Position is A$2.69 Mil.
How does Resonance Health's Ending Cash Position compare to VEEV and BTSG?
Resonance Health's Ending Cash Position of A$2.69 Mil can be compared against companies in the Healthcare Providers & Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Ending Cash Position for a Healthcare Providers & Services company?
A good Ending Cash Position depends on the Healthcare Providers & Services industry context. However, Ending Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Ending Cash Position mean?
A high Ending Cash Position can signal that a stock is expensive relative to its fundamentals. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Resonance Health and its competitors. Resonance Health's current Ending Cash Position is A$2.69 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Resonance Health stock overvalued right now?
Based on GuruFocus' analysis, Resonance Health (ASX:RHT) is currently considered Possible Value Trap. The stock's GF Value™ is A$0.12, compared to a current price of A$0.06 — trading 53.3% below its estimated fair value. The current Ending Cash Position is A$2.69 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Ending Cash Position calculated?
Ending Cash Position is calculated from a company's financial statements. For Resonance Health (ASX:RHT), the current Ending Cash Position is A$2.69 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Resonance Health Business Description

Address 141 Burswood Road, Level 1, Burswood, Perth, WA, AUS, 6100
Resonance Health Ltd is engaged in the development and commercialisation of software-as-medical-device (SaMD) technologies and services for the quantitative analysis of radiological images in a regulated and quality-controlled environment. The Group's core SaMD product is FerriScan, a non-invasive liver analysis technology used for the assessment of iron in the liver. The Company also has several AI-assisted SaMDs including FerriSmart, HepaFatSmart, and LiverSmart. Its business segments are; SaMD1 which derives key revenue, Corporate, TrialsWest, and Resonance Clinica. Geographically, it generates maximum revenue from the Asia Pacific region and the rest from North America, and Europe, Middle East and Africa (EMEA) regions.